For some patients with bladder cancer, neoadjuvant chemotherapy plus bladder-saving concurrent chemoradiation therapy was ...

Background: Despite undergoing surgery and chemoradiotherapy, patients with first primary lung cancer (FPLC) remain at risk for second primary lung cancer (SPLC), which is associated with a poor ...

During the past 20 years, the advent of neoadjuvant, primary, and adjuvant concurrent chemoradiotherapy has improved cancer care dramatically. Significant contributions have been made by ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Background: Currently, the value of induction chemoimmunotherapy before chemoradiotherapy (CRT) in unresectable stage III non-small cell lung cancer (NSCLC) has not been explored. This study was ...

GOBLET study: Results of the safety run-in for first-line metastatic pancreatic ductal adenocarcinoma (PDAC) patients treated with pelareorep + modified FOLFIRINOX +/- atezolizumab. This is an ASCO ...

肺癌是我国及世界范围内发病率和死亡率最高的恶性肿瘤之一，非小细胞肺癌（NSCLC）约占肺癌的 85%，1/3 的患者在确诊时已为局部晚期 NSCLC，5 年生存率仅 13% ~ 16%。其中，N2 期肺癌患者预后更差，手术切除后 3 年生存率仅 9% ...

Preoperative sintilimab with chemoradiotherapy boosted pathological complete response rates in patients with resectable, locally advanced esophageal squamous cell carcinoma. Adding sintilimab (Tyvyt) ...

A phase Ib study of immunotherapy with ex-vivo pre-activated and expanded CBNK cells in combination with cetuximab, in patients with colorectal cancer (CRC) with minimal residual disease (MRD): Final ...

For patients with resectable esophageal adenocarcinoma, perioperative chemotherapy with FLOT leads to improved survival compared with preoperative chemoradiotherapy.